Good afternoon and thank you for joining us on today's call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference call is being recorded today, August 14th, 2019. I would now like to turn the conference call over to Scott Youngstrom, CFO of ReShape Lifesciences. Please go ahead.

Good afternoon and thank you for joining us on today's call. I'm pleased to be joined by Bart Bandy, our Chief Executive Officer, who will provide an overview of the company's recent activities and business highlights. I will then review our financial results for the second quarter of 2019 and then turn the call back over to Bart to wrap-up the call. As a reminder, this conference call as well as ReShape Lifesciences' SEC filings and website at www.reshapelifesciences.com including the Investor Information section of the website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially from those discussed due to the known and unknown risks, uncertainties, and other factors. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as Risk Factors in our annual report on Form 10-K that was filed on May 16th, 2019, and in our quarterly report on Form 10-Q that is anticipated to be filed no later than August 19th, 2019. As an additional reminder, our stock is listed OTCQB trading under the ticker RSLS. I will now turn the call over to our CEO, Bart Bandy. Bart?

Thanks Scott. Good afternoon everyone and thank you for dialing in to our call today. I'm pleased to be hosting ReShape Lifesciences' second quarter earnings call. On today's call, I will share with you the exciting progress we've made in the past few months of ReShape, operationally; financially; and technically, as well as the strategy we have put into place over the past few months and how this supports our vision as we move forward. Scott will then provide an overview of our financial results, and then I will wrap things up. Let's start with our topline, which we are incredibly proud of. Total revenues in the second quarter were $4.4 million, representing a 42% increase over our revenues of $3.1 million in the first quarter of this year. You might remember that when we acquired LAP-BAND, our goal was to reduce the decline that the project have been experiencing in the years prior to the acquisition. Only two quarters of owning the product, we have not only achieved that goal in the U.S., but our U.S. sales of LAP-BAND actually grew compared to the second quarter of 2018 under previous leadership and ownership. Our revenues in second quarter of 2019 compared to $653,000 revenue in the year ago quarter, all of which was derived from gastric balloon sales, which has since been discontinued. And while we were a very different company in the second quarter of 2018 with different products, the significant revenue increase in one year speaks volumes to the fact that we are on the right track with the right product, the right strategy and the right team. To talk a bit more about the strategy, we mentioned on our last call that I spent significant time in my first month at ReShape, researching and reconnecting with…

Thanks Bart and good afternoon everybody. For purposes of this quarterly financial update, we will be comparing our June 30th, 2019 results to our March 31st, 2019 results for both revenue and gross margins, as any comparison to prior year is not comparable due to the acquisition of the LAP-BAND product line and the discontinuance of the intra-gastric balloon product line in December of 2018. For the three months ended June 30th, 2019, we reported sales of $4.4 million as compared to revenues of $3.1 million in the three months ended March 31st, 2019, which represents a 42% increase. Our revenue numbers reflect $2.8 million in U.S. shipments and $1.5 million from shipments outside the U.S., which include shipments to Apollo Europe as a part of our transition services agreement. As a reminder, our OUS revenue now consists of direct sales to our Australian customers, combined with sales in Europe, which will continue to go through Apollo at a transfer price until we finalize our commercial infrastructure in Europe. We continue to work to bring this opportunity in-house with the target date of late quarter three, so that we can begin to recognize these global revenues. We reported gross profit of $2.9 million in the second quarter of 2019 at a the gross margin of 64%, compared to $2.2 million in gross profit in the three months ended March 31st, 2019 at a gross margin of 73%. The lower gross margin is primarily the result of an increase in our mix of sales in Europe, as our revenue from shipments to Europe carry a lower gross margin than our U.S. revenues due to our transfer pricing arrangement with Apollo. The Q2 gross margin of 64% is right in line with our expectations and why we initially forecasted fully transitioning the…

Thanks Scott. Our team is working incredibly hard this past quarter to show the world that the LAP-BAND is back and that we have a solid strategy and a suite of products dedicated to this market. We've traveled the globe to meet the customers, both existing and new, and worked diligently to understand the market and how we can best service surgeons and patients. We're now set up with a strategy and pathway for success, and we are optimistic for the road ahead. Thank you to our investors, Board, employees, and customers, who step by our side and for listening to our call today. End of Q&A: Ladies and gentlemen, thank you for participating in today's conference. This concludes today's program and you may all disconnect. Everyone, have a wonderful day.